Pfizer’s coronavirus vaccine shows moderate side-effects in clinical study

pharmafile | September 16, 2020 | News story | Research and Development COVID-19, Pfizer, Pfizer vaccine, coronavirus vaccine 

Pfizer has said that participants in a late-stage trial for its COVID-19 vaccine candidate have shown mild to moderate side effects. 

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with BioNTech. Over 12,000 study participants have received a second dose of the vaccine. 

Unlike the AstraZeneca study which was forced to come to a halt recently, the Pfizer trial is not being paused as the symptoms shown are not severe or life-threatening. 

Fatigue was the most common side-effect, but researchers do not yet know how much of the affected had received the vaccine or a placebo; 36% of the 18 to 64 age group and 27% of the 65 to 84 group reported this symptom. After fatigue, the most common reported side-effects were headaches, muscle pain, joint pain and chills. 

In a company call, Dr Kathrin Janson, the Head of Research at Pfizer, said that researchers would “notify us if they had any safety concerns and have not done that to date.”

Conor Kavanagh

Related Content

CDC Advisory Committee recommends Pfizer’s RSV vaccine

Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

Latest content